CANCER RES 润色咨询

CANCER RESEARCH

出版年份:1941 年文章数:12632 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:2.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-08-25 ms7000002977722170 来自北京

    总共耗时约 5 个月。
    投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。
    两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。
    总体来说期刊的审稿周期在同类型期刊中算比较快的。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-08-05 ms6000001159276722 来自东京都

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫
    经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。
    初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2026-02-01 1811e984f8m 来自安徽省

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向:蛋白质翻译后修饰
    经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-11-12 ms8000001953403022 来自陕西省

    偏重的研究方向:肿瘤学;医学
    经验分享:Under Review 2025-11-10 11:00:29
    Under Editorial Consideration 2025-11-03 05:58:58
    Initial QC 2025-11-02 04:04:02
    Manuscript Submission 2025-11-02 02:55:35
    已投稿,Under Review2天,结果未知。

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-08-31 ms7000002977722171 来自上海

    投稿后,7 天完成编辑邀请(共 2 位编辑)
    10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)
    虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。
    说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-04-09 ms8000000289511534 来自四川省

    请问需要审稿费么?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-06-15 ms6000002977722166 来自上海

    一审意见基本是2-3周内返回,若需修改,1-2个月内完成。
    若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。
    此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。
    若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2024-12-30 ms4000000265024223 来自山东省

    偏重的研究方向:肿瘤基础研究
    经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭

    8

    展开8条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-02-18 Mr.Never Die 来自上海

    偏重的研究方向:蛋白质翻译后修饰
    经验分享:能行吗 肿瘤的蛋白ptm 能中吗

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2278741, encodeId=d68722e8741c4, content=总共耗时约 5 个月。<br>投稿后,稿件很快进入编辑处理阶段,7天就完成了邀请编辑的流程,我那篇文章邀请了2 位编辑。一审送审时间较快,在投稿后的第10天就送审了,一审意见在 3 周后返回。<br>两个审稿人给出的意见,一个建议小修,一个要求大修,编辑综合后给了大修的决定,并给了 2 个月的修改时间。我在 1 个半月内完成修改并重新提交。二审送审时间是重新提交后的第 5 天,二审7天,最终成功接收。<br>总体来说期刊的审稿周期在同类型期刊中算比较快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722170, createdTime=Mon Aug 25 23:49:58 CST 2025, time=2025-08-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2276105, encodeId=76ae22e6105d6, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:基因编辑;非小细胞肺癌;肿瘤免疫<br>经验分享:刚收到预接收邮件,在这里感谢同道‘147ce2ffm38(暂无昵称)’提供的投稿经验。本人的工作为某个技术性工作(不仅可用于肿瘤研究)在肿瘤方面的应用,所以最早投在NC上并未被接收。后转投到CR,因为审稿人也都是肿瘤领域的研究人员,对于该技术在肿瘤研究方面的应用价值非常认可。<br>初稿投过去一周收到送外审的邮件,外审2-4周(基本上都会拖到4周),随后返回editor,2天后收到邮件,两个建议小修一个建议大修,给了三个月补实验,另外需要补充一些信息(CR在这方面要求还挺严格),比如各种抗体细胞的RRID等。投回后5天后送外审,外审给了3周,回来到editor手里UER又经过2周+1天,告知预接收。随后需要每个作者申请ORCID账号,填写一些和研究经费/利益相关的问卷。另外每个作者的邮箱均要求更改为学校/科研机构邮箱,而不能是个人商业邮箱(不能用网易或者QQ)。其它格式方面的要求不再赘述。也祝各位同道都能够投稿顺利!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdfb8142562, createdName=ms6000001159276722, createdTime=Tue Aug 05 13:49:54 CST 2025, time=2025-08-05, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2299317, encodeId=ccda229931e05, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:蛋白质翻译后修饰<br>经验分享:肿瘤基础研究的标杆期刊,受广泛认可。即时影响因子超过20分,投稿难度将越来大。目前看,投稿录用率只有5%左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Feb 01 09:10:21 CST 2026, time=2026-02-01, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2288628, encodeId=41db228862877, content=偏重的研究方向:肿瘤学;医学<br>经验分享:Under Review 2025-11-10 11:00:29<br>Under Editorial Consideration 2025-11-03 05:58:58<br>Initial QC 2025-11-02 04:04:02<br>Manuscript Submission 2025-11-02 02:55:35<br>已投稿,Under Review2天,结果未知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e36485006, createdName=ms8000001953403022, createdTime=Wed Nov 12 15:49:27 CST 2025, time=2025-11-12, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2279449, encodeId=a05a22e944982, content=投稿后,7 天完成编辑邀请(共 2 位编辑)<br>10天进入一审,3 周后收到审稿意见 (1 位小修、1 位大修,编辑最终要求大修并给 2 个月修改期。)<br>虽然1个半月内返稿,5 天后进入二审且 7 天完成,但仍未通过。<br>说是对大修审稿人提出的核心实验补充建议回应不够充分,仅浅层修改什么的,后续再重新奋斗吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:29:07 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259727, encodeId=f4cd2259e2747, content=请问需要审稿费么?<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83988836455, createdName=ms8000000289511534, createdTime=Wed Apr 09 13:36:34 CST 2025, time=2025-04-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2269523, encodeId=636e226952300, content=一审意见基本是2-3周内返回,若需修改,1-2个月内完成。<br>若作者对一审意见有疑问,可礼貌地向编辑部提出申诉,但需注意,申诉过程可能延长审稿周期。<br>此外,期刊鼓励作者使用英文撰写,语言表达需准确流畅,必要时可请专业润色服务提升语言质量。<br>若作者希望加快出版速度,可选择开放获取(OA)模式,但需额外支付文章处理费(APC)2300美元。总体而言,《Cancer Research》是一本对高质量研究有较高要求的期刊,但其审稿效率和学术影响力使其成为许多肿瘤学研究者的首选目标。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=166, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722166, createdTime=Sun Jun 15 18:13:33 CST 2025, time=2025-06-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2245612, encodeId=e68a2245612be, content=偏重的研究方向:肿瘤基础研究<br>经验分享:请问最近cancer research的编辑还在过节吗?快十天了还没做决定😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Mon Dec 30 16:33:58 CST 2024, time=2024-12-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2252518, encodeId=0fc92252518a1, content=偏重的研究方向:蛋白质翻译后修饰<br>经验分享:能行吗 肿瘤的蛋白ptm 能中吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Tue Feb 18 17:00:53 CST 2025, time=2025-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248334, encodeId=9fd82248334a4, content=偏重的研究方向:肿瘤基础研究<br>经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Thu Jan 16 14:18:09 CST 2025, time=2025-01-16, status=1, ipAttribution=山东省)]
    2025-01-16 dr_NEO 来自山东省

    偏重的研究方向:肿瘤基础研究
    经验分享:收到external peer review邮件42天系统状态还是under review这正常吗😭

    3

    展开3条回复
共429条页码: 1/43页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分